{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"In the Interim...","title":"The CHIPS Trial: Bayesian Adaptive Trial in JAMA","html":"","width":"100%","height":180,"duration":2740,"description":"In this episode of “In the Interim…,” Dr. Scott Berry talks with Dr. Roger Lewis, Dr. Anna McGlothlin, and Dr. Nick Berry — all co-authors on the CHIPS trial results recently published in JAMA (Spinella et al., August 2026) — about the design, implementation, and results. The conversation covers why room-temperature platelets, which can be stored only five to seven days, leave rural hospitals, low-volume centers, and military and disaster settings without a reliable supply, and how a Bayesian adaptive design was used to find the maximum safe cold-storage duration rather than testing a single fixed duration. Roger, Anna, and Nick walk through the monotonic dose-response model that governed escalation, an unplanned mid-trial complication when the FDA independently authorized fourteen-day cold storage, and how the Data Safety Monitoring Board reviewed results within days of each interim. The trial ultimately demonstrated non-inferiority of cold-stored platelets out to twenty-one days with a Bayesian probability greater than 99.9%, offering a path to expanding platelet access in settings where it was previously very challenging.\nKey Highlights\nCold-stored platelets tested as a potential answer to platelet shortages in rural, low-volume, and military/disaster settings.\nBayesian adaptive design used to find the maximum safe cold-storage duration, not just test a single fixed duration.\nA monotonic dose-response model constrained escalation to a pre-specified, safety-first ladder across four interim analyses.\nMid-trial complication: an independent FDA decision allowing 14-day cold storage, absorbed into the design without unblinding.\nNon-inferiority demonstrated out to 21 days of cold storage, with a Bayesian probability greater than 99.9%.\nInterim data turned around by the unblinded implementation team in five business days, versus the six weeks often assumed for adaptive trials.\nImplications for platelet access in disaster, military, and low-volume hospital settings,...","thumbnail_url":"https://img.transistorcdn.com/toFATB0JXvqQXRqzUqrK1EWCJCLOA_Qvjkb5ml3q-s8/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9jM2M0/ZDE2YzA1N2FhNjkx/NDk1NDczNjYzM2E5/NjlmYS5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}